Try our beta test site

Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2005 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
Beth Israel Deaconess Medical Center
Information provided by:
Hadassah Medical Organization Identifier:
First received: December 4, 2005
Last updated: March 19, 2007
Last verified: November 2005
The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.


Study Type: Observational
Study Design: Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Estimated Enrollment: 200
Study Start Date: November 2005
Detailed Description:

Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.

We intend to check the angiogenesis profile of primiparas as compared to multiparas.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Every delivery

Exclusion Criteria:

  • Preeclampsia or pregnancy induced hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00262093

Contact: Yuval Bdolah, MD, MSc 972-2-5844111
Contact: Hadas Lemberg, PhD 972-2-6777572

Hadassah Medical Organization Recruiting
Jerusalem, Israel, 91240
Contact: Arik Tzukert, DMD    972 2 6776095   
Contact: Hadas Lemberg, PhD    972 2 6777572   
Principal Investigator: Yuval Bdolah, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Beth Israel Deaconess Medical Center
Principal Investigator: Yuval Bdolah, MD, MSc Hadassah-Hebrew University Medical School
  More Information Identifier: NCT00262093     History of Changes
Other Study ID Numbers: PRIMIMULTI-HMO-CTIL 
Study First Received: December 4, 2005
Last Updated: March 19, 2007

Keywords provided by Hadassah Medical Organization:

Additional relevant MeSH terms:
Hypertension, Pregnancy-Induced
Pregnancy Complications processed this record on February 24, 2017